
  
    
      
        
        The_DT consequence_NN of_IN Parkinson_NNP 's_POS disease_NN (_( PD_NNP )_) is_VBZ well_RB described_VBN :_: a_DT progressive_JJ movement_NN
        disorder_NN that_IN ,_, whilst_NN responding_VBG to_TO symptomatic_JJ therapy_NN ,_, chronically_RB disables_NNS its_PRP$ sufferers_NNS
        and_CC adds_VBZ an_DT enormous_JJ economic_JJ burden_NN in_IN an_DT aging_VBG society_NN ._. We_PRP have_VBP some_DT clues_NNS to_TO the_DT process_NN
        underlying_VBG the_DT disease_NN from_IN the_DT snapshot_NN provided_VBN by_IN postmortem_NN studies_NNS of_IN diseased_JJ brains_NNS ._.
        Groups_NNS of_IN neurons_NNS in_IN specific_JJ brain_NN regions_NNS are_VBP lost_VBN ,_, notably_RB those_DT that_WDT produce_VBP dopamine_NN
        in_IN a_DT part_NN of_IN the_DT midbrain_NN called_VBD the_DT substantia_NN nigra_NN ._. Those_DT neurons_NNS that_WDT do_VBP survive_VB to_TO the_DT
        end_NN of_IN the_DT disease_NN course_NN contain_VB accumulations_NNS of_IN proteins_NNS and_CC lipids_NNS within_IN their_PRP$
        cytoplasm_NN ._. Named_VBN after_IN their_PRP$ discoverer_NN ,_, these_DT “ Lewy_NNP bodies_NNS” are_VBP one_CD piece_NN of_IN evidence_NN that_DT
        protein_NN aggregation_NN is_VBZ related_VBN to_TO the_DT ongoing_JJ disease_NN process_NN ._.
        In_IN contrast_NN ,_, the_DT causes_NNS of_IN PD_NNP are_VBP poorly_RB defined_VBN except_IN in_IN those_DT rare_JJ variant_NN forms_NNS that_WDT
        are_VBP clearly_RB genetic_JJ ._. Several_JJ families_NNS have_VBP been_VBN described_VBN where_WRB PD-like_NNP syndromes_NNS are_VBP
        inherited_VBN in_IN either_DT a_DT dominant_JJ or_CC recessive_JJ fashion_NN ,_, and_CC four_CD of_IN the_DT underlying_VBG genes_NNS have_VBP
        been_VBN identified_VBN ._. The_DT precise_JJ relationships_NNS between_IN these_DT different_JJ syndromes_NNS are_VBP complex_JJ
        and_CC are_VBP the_DT subject_NN of_IN some_DT controversy_NN ._. For_IN example_NN ,_, it_PRP is_VBZ not_RB clear_JJ whether_IN all_PDT the_DT
        genetic_JJ diseases_NNS given_VBN PARK_NNP nomenclature_NN have_VBP Lewy_NNP bodies_NNS and_CC should_MD be_VB considered_VBN “ true_JJ”
        PD—the_NNP term_NN parkinsonism_NN is_VBZ preferred_VBN for_IN these_DT syndromes_NNS (_( Hardy_NNP and_CC Langston_NNP 2004_CD )_) ._. For_IN
        the_DT purposes_NNS of_IN this_DT primer_NN ,_, I_PRP will_MD concentrate_VB on_IN the_DT molecular_JJ biology_NN of_IN the_DT genes_NNS
        linked_VBN to_TO PD_NNP rather_RB than_IN disease_NN etiology_NN ._. However_RB ,_, my_PRP$ assumption_NN is_VBZ that_IN symptoms_NNS of_IN the_DT
        disease_NN are_VBP a_DT reflection_NN of_IN neuronal_NN dysfunction_NN ,_, and_CC that_IN in_IN the_DT disease_NN state_NN the_DT balance_NN
        between_IN damage_NN and_CC survival_NN tips_NNS in_IN the_DT direction_NN of_IN cell_NN loss_NN ._. Whilst_NNP dominant_JJ mutations_NNS
        overwhelm_VBP the_DT ability_NN of_IN cells_NNS to_TO survive_VB ,_, recessive_JJ mutations_NNS result_VBP in_IN the_DT absence_NN of_IN
        protective_JJ proteins_NNS and_CC make_VB the_DT neuron_NN grow_VB weaker_JJR ._.
      
      
        Aggregation_NNP of_IN α-_NN Synuclein_NNP in_IN Neurodegeneration_NNP
        On_IN the_DT detrimental_JJ side_NN of_IN the_DT cell_NN survival_NN equation_NN is_VBZ the_DT PD_NNP gene_NN that_WDT was_VBD discovered_VBN
        first_JJ ,_, α_NN
        -_: synuclein_NN ._. The_DT synaptic_JJ protein_NN encoded_JJ by_IN this_DT gene_NN ,_, α-synuclein_JJ ,_, is_VBZ
        prone_JJ to_TO aggregation_NN ,_, and_CC ,_, as_IN is_VBZ the_DT case_NN for_IN other_JJ aggregating_VBG proteins_NNS ,_, mutations_NNS in_IN α-_NN
        synuclein_NN are_VBP associated_VBN with_IN dominantly_RB inherited_VBN disease_NN ._. Related_NNP to_TO
        this_DT ,_, α-synuclein_JJ is_VBZ a_DT major_JJ protein_NN component_NN of_IN Lewy_NNP bodies_NNS ._. The_DT phenotype_NN of_IN patients_NNS
        with_IN α-_NN
        synuclein_NN mutations_NNS varies_VBZ from_IN PD_NNP to_TO a_DT more_JJR diffuse_NN Lewy_NNP body_NN disease_NN in_IN
        which_WDT pathology_NN is_VBZ detected_VBN in_IN the_DT cerebral_JJ cortex_NN and_CC other_JJ areas_NNS of_IN the_DT brain_NN ._. Mutations_NNP
        in_IN α-_NN
        synuclein_NN include_VBP three_CD point_NN mutations_NNS (_( A_DT 30_CD P_NN ,_, E_NNP 46_CD K_NNP ,_, and_CC A_DT 53_CD T_NN )_) and_CC
        multiplication_NN of_IN the_DT wild-type_JJ (_( normal_JJ )_) gene_NN ._. All_DT of_IN these_DT mutations_NNS increase_VBP the_DT tendency_NN
        of_IN α-synuclein_JJ to_TO aggregate_JJ ,_, suggesting_VBG that_DT disease_NN is_VBZ a_DT consequence_NN of_IN protein_NN
        aggregation_NN ._. An_DT interesting_JJ example_NN is_VBZ the_DT triplication_NN of_IN the_DT wild-type_JJ gene_NN :_: toxicity_NN and_CC
        aggregation_NN can_MD both_DT be_VB driven_VBN by_IN increased_VBN expression_NN and_CC are_VBP thus_RB qualitative_JJ ,_, not_RB
        quantitative_JJ ,_, effects_NNS (_( Singleton_NNP et_CC al_NN ._. 2003_CD )_) ._. The_DT fact_NN that_IN the_DT wild-type_JJ protein_NN can_MD
        aggregate_JJ suggests_VBZ that_IN the_DT process_NN is_VBZ fundamentally_RB similar_JJ for_IN both_DT inherited_VBN and_CC
        sporadic_JJ PD_NNP in_IN which_WDT wild-type_JJ α-synuclein_JJ is_VBZ also_RB present_JJ in_IN Lewy_NNP bodies_NNS ._. Several_JJ
        commentators_NNS have_VBP suggested_VBN that_IN non-genetic_JJ risk_NN factors_NNS may_MD also_RB promote_VB damage_NN via_IN their_PRP$
        effects_NNS on_IN (_( wild-type_JJ )_) α-synuclein_JJ conformation_NN or_CC aggregation_NN (_( e_SYM ._. g_SYM ._. ,_, Di_NNP Monte_NNP 2003_CD )_) ._. This_DT
        reinforces_VBZ the_DT notion_NN that_IN α-synuclein_JJ is_VBZ central_JJ to_TO the_DT pathogenesis_NNS of_IN both_DT sporadic_JJ and_CC
        familial_NN PD_NNP ._.
        There_EX is_VBZ some_DT controversy_NN about_IN the_DT exact_JJ nature_NN of_IN the_DT toxic_JJ species_NNS produced_VBN by_IN
        α-synuclein_JJ ,_, as_IN one_CD point_NN mutation_NN (_( A_DT 30_CD P_NN )_) behaves_VBZ differently_RB from_IN the_DT others_NNS ._. Instead_RB of_IN
        forming_VBG fibrils_NNS ,_, which_WDT are_VBP insoluble_JJ ,_, high-molecular-weight_JJ species_NNS ,_, A_DT 30_CD P_NN forms_NNS relatively_RB
        soluble_JJ ,_, partially_RB aggregated_JJ species_NNS (_( Conway_NNP et_CC al_NN ._. 2000_CD )_) ._. These_DT intermediate-sized_JJ
        protein_NN aggregates_NNS are_VBP referred_VBN to_TO as_IN oligomers_NNS or_CC protofibrils_NNS ._. Some_DT authors_NNS have_VBP argued_VBN
        that_IN since_IN A_DT 30_CD P_NN causes_NNS disease_NN ,_, oligomers_NNS /_NN protofibrils_NNS are_VBP the_DT authentic_JJ toxic_JJ species_NNS ._. It_PRP
        is_VBZ generally_RB assumed_VBN that_IN fibrils_NNS are_VBP the_DT form_NN of_IN α-synuclein_JJ deposited_VBN into_IN Lewy_NNP bodies_NNS ,_,
        but_CC whether_IN Lewy_NNP bodies_NNS damage_VBP cells_NNS is_VBZ controversial_JJ ._. One_CD possibility_NN is_VBZ that_IN by_IN
        sequestering_NN α-synuclein_JJ into_IN this_DT insoluble_JJ body_NN and_CC compartmentalizing_VBG the_DT potentially_RB
        toxic_JJ species_NNS away_RB from_IN possible_JJ targets_NNS in_IN the_DT cytoplasm_NN ,_, the_DT Lewy_NNP body_NN represents_VBZ an_DT
        attempt_NN of_IN the_DT cell_NN to_TO protect_VB itself_PRP (_( Olanow_NNP et_CC al_NN ._. 2004_CD )_) ._.
        Whether_IN the_DT Lewy_NNP body_NN is_VBZ damaging_JJ or_CC neuroprotective_JJ ,_, there_EX are_VBP clearly_RB several_JJ possible_JJ
        targets_NNS for_IN toxic_JJ α-synuclein_JJ within_IN the_DT cell_NN ._. For_IN example_NN ,_, aggregated_JJ α-synuclein_JJ can_MD
        permeabilize_NN cellular_JJ membranes_NNS and_CC thus_RB might_MD damage_VB organelles_NNS (_( Volles_NNP and_CC Lansbury_NNP
        2003_CD )_) ._. Mitochondrial_NNP function_NN and_CC synaptic_JJ transmission_NN may_MD be_VB especially_RB affected_VBN ,_, and_CC
        both_DT of_IN these_DT can_MD secondarily_RB increase_VB oxidative_JJ stress_NN within_IN the_DT cytosol_NN (_( Greenamyre_NNP and_CC
        Hastings_NNP 2004_CD )_) ._. When_WRB overexpressed_JJ ,_, mutant_JJ α-synuclein_JJ can_MD inhibit_VB the_DT proteasome_NN
        (_( Petrucelli_NNP et_CC al_NN ._. 2002_CD )_) ,_, a_DT multiprotein_NN complex_JJ that_WDT degrades_NNS many_JJ unwanted_JJ or_CC
        inappropriate_JJ proteins_NNS in_IN cells_NNS ._. Mutant_NNP forms_NNS of_IN α-synuclein_JJ also_RB inhibit_VB
        chaperone-mediated_JJ autophagy_NN ,_, another_DT important_JJ protein_NN turnover_NN pathway_NN that_WDT involves_VBZ
        lysosomes_NNS (_( Cuervo_NNP et_CC al_NN ._. 2004_CD )_) ._. Between_IN these_DT two_CD effects_NNS ,_, it_PRP is_VBZ likely_JJ that_IN cells_NNS with_IN
        aggregated_JJ α-synuclein_JJ will_MD become_VB less_RBR able_JJ to_TO handle_VB damaged_VBN or_CC misfolded_JJ proteins_NNS ._. It_PRP is_VBZ
        also_RB possible_JJ that_IN other_JJ cellular_JJ processes_NNS that_IN we_PRP have_VBP not_RB yet_RB identified_VBN are_VBP affected_VBN by_IN
        the_DT presence_NN of_IN this_DT protein_NN that_WDT has_VBZ such_JJ an_DT innate_JJ tendency_NN to_TO aggregate_JJ ._.
        Presumably_RB ,_, neurons_NNS require_VBP α-synuclein_JJ for_IN their_PRP$ normal_JJ function_NN and_CC thus_RB cannot_NN simply_RB
        dispense_VB with_IN this_DT protein_NN that_WDT has_VBZ toxic_JJ properties_NNS ,_, although_IN mice_NNS in_IN which_WDT the_DT α-_NN
        synuclein_NN gene_NN is_VBZ knocked_VBN out_IN have_VBP no_DT obvious_JJ deficits_NNS (_( see_VB Dauer_NNP and_CC
        Przedborski_NNP [_NN 2003_CD ]_NN for_IN discussion_NN )_) ._.
      
      
        Parkin_NNP ,_, DJ-_NNP 1_CD ,_, and_CC PINK_NNP 1_CD in_IN Neuroprotection_NNP
        Evolution_NNP has_VBZ provided_VBN cells_NNS with_IN many_JJ ways_NNS to_TO protect_VB themselves_PRP ._. As_IN we_PRP will_MD see_VB ,_,
        mutations_NNS that_WDT cause_VBP recessive_JJ diseases_NNS result_VBP in_IN the_DT loss_NN of_IN these_DT neuroprotective_JJ
        functions_NNS ._. The_DT genes_NNS involved_VBN in_IN recessive_JJ parkinsonism_NN are_VBP ,_, in_IN order_NN of_IN discovery_NN ,_, 
        parkin_NN ,_, DJ-_NNP 1_CD ,_, and_CC 
        PINK_NNP 1_CD ._. The_DT three_CD protein_NN products_NNS of_IN these_DT genes_NNS all_DT have_VBP different_JJ
        functions_NNS ,_, thus_RB implicating_VBG several_JJ different_JJ cellular_JJ functions_NNS in_IN neuroprotection_NN ._. Parkin_NNP
        is_VBZ an_DT E_NNP 3_CD ubiquitin–protein_NN ligase_NN ,_, promoting_VBG the_DT addition_NN of_IN ubiquitin_NN to_TO target_VB proteins_NNS
        prior_RB to_TO their_PRP$ degradation_NN by_IN the_DT proteasome_NN ._. The_DT identification_NN of_IN parkin_NN 's_POS function_NN was_VBD
        facilitated_JJ by_IN the_DT observation_NN that_IN the_DT protein_NN contains_VBZ a_DT RING_NNP finger_NN (_( Zhang_NNP et_CC al_NN ._. 2000_CD )_) ,_,
        a_DT common_JJ motif_NN amongst_IN this_DT class_NN of_IN E_NNP 3_CD enzymes_NNS ._. Several_JJ parkin_NN substrates_NNS have_VBP been_VBN
        proposed_VBN ,_, and_CC at_IN least_JJS two_CD are_VBP damaging_JJ to_TO neurons_NNS if_IN they_PRP are_VBP allowed_VBN to_TO accumulate_VBP (_( Dong_NNP
        et_CC al_NN ._. 2003_CD ;_: Yang_NNP et_CC al_NN ._. 2003_CD )_) ._. Therefore_RB ,_, our_PRP$ best_JJS evidence_NN to_TO date_NN indicates_VBZ that_IN parkin_NN
        benefits_VBZ neurons_NNS by_IN removing_VBG proteins_NNS that_WDT might_MD otherwise_RB damage_VB the_DT cell_NN ._. In_IN fact_NN ,_,
        expression_NN of_IN parkin_NN is_VBZ neuroprotective_JJ in_IN a_DT number_NN of_IN contexts_NNS ,_, and_CC there_EX is_VBZ even_RB evidence_NN
        for_IN a_DT beneficial_JJ effect_NN of_IN this_DT E_NNP 3_CD ligase_NN on_IN mitochondrial_NN function_NN (_( Shen_NNP and_CC Cookson_NNP
        2004_CD )_) ._.
        Data_NNS on_IN PINK_NNP 1_CD are_VBP limited_JJ ,_, but_CC the_DT protein_NN contains_VBZ two_CD motifs_NNS that_WDT indicate_VBP its_PRP$ likely_JJ
        cellular_JJ role_NN ._. At_IN the_DT amino-terminus_JJ of_IN PINK_NNP 1_CD is_VBZ a_DT mitochondrial-targeting_JJ sequence_NN ,_, and_CC
        mitochondrial_NN localization_NN has_VBZ been_VBN confirmed_VBN in_IN the_DT one_CD study_NN published_VBN to_TO date_NN (_( Valente_NNP
        et_CC al_NN ._. 2004_CD )_) ._. Most_JJS of_IN the_DT rest_NN of_IN PINK_NNP 1_CD is_VBZ a_DT Serine_NNP /_NN Threonine_NNP protein_NN kinase_NN domain_NN ,_,
        followed_VBN by_IN a_DT short_JJ carboxy-terminal_JJ region_NN of_IN unclear_JJ significance_NN ._. The_DT substrates_NNS of_IN
        PINK_NNP 1_CD have_VBP not_RB yet_RB been_VBN identified_VBN ,_, but_CC presumably_RB phosphorylation_NN of_IN these_DT substrates_NNS
        controls_NNS some_DT critical_JJ function_NN for_IN neuronal_NN survival_NN ._. In_IN their_PRP$ paper_NN ,_, Valente_NNP and_CC
        colleagues_NNS show_VBP that_IN PINK_NNP 1_CD decreases_NNS damage_VBP to_TO mitochondria_NN induced_VBN by_IN proteasome_NN
        inhibition_NN ,_, but_CC a_DT recessive_JJ mutant_JJ PINK_NNP 1_CD is_VBZ unable_JJ to_TO protect_VB cells_NNS ._.
        The_DT discussion_NN of_IN protein_NN functions_NNS gets_VBZ more_RBR complicated_JJ in_IN the_DT case_NN of_IN DJ-_NNP 1_CD ._. Unlike_IN
        parkin_NN or_CC PINK_NNP 1_CD ,_, there_EX are_VBP no_DT motifs_NNS within_IN DJ-_NNP 1_CD that_DT hint_NN strongly_RB at_IN a_DT single_JJ function_NN ._.
        Instead_RB ,_, 
        DJ-_NNP 1_CD is_VBZ a_DT member_NN of_IN a_DT large_JJ superfamily_RB of_IN genes_NNS with_IN several_JJ different_JJ
        functions_NNS across_IN species_NNS (_( Bandyopadhyay_NNP and_CC Cookson_NNP 2004_CD )_) ._. These_DT include_VBP proteases_NNS in_IN
        thermophilic_JJ bacteria_NNS ,_, transcription_NN factors_NNS ,_, and_CC chaperones_NNS that_WDT promote_VBP protein_NN
        refolding_VBG ._. Several_JJ research_NN groups_NNS have_VBP published_VBN data_NNS in_IN support_NN of_IN DJ-_NNP 1_CD having_VBG one_CD or_CC
        more_JJR of_IN these_DT activities_NNS ,_, including_VBG the_DT report_NN ,_, published_VBN in_IN this_DT issue_NN of_IN 
        PLoS_NNP Biology_NNP ,_, that_IN DJ-_NNP 1_CD is_VBZ a_DT molecular_JJ chaperone_NN that_WDT regulates_VBZ
        α-synuclein_JJ ,_, among_IN other_JJ molecules_NNS (_( Shendelman_NNP et_CC al_NN ._. 2004_CD )_) ._. It_PRP is_VBZ not_RB yet_RB firmly_RB
        established_VBN which_WDT activity_NN of_IN DJ-_NNP 1_CD is_VBZ most_RBS relevant_JJ to_TO recessive_JJ parkinsonism_NN ._. The_DT
        important_JJ function_NN of_IN DJ-_NNP 1_CD might_MD be_VB unrelated_JJ to_TO any_DT of_IN the_DT above_JJ activities_NNS ._. For_IN example_NN ,_,
        there_EX are_VBP several_JJ roles_NNS of_IN this_DT protein_NN in_IN modulation_NN of_IN transcriptional_NN responses_NNS ,_, which_WDT
        may_MD be_VB critical_JJ in_IN maintaining_VBG neuronal_NN viability_NN (_( Bonifati_NNP et_CC al_NN ._. 2003_CD and_CC references_NNS
        therein_RB )_)
        DJ-_NNP 1_CD is_VBZ also_RB known_VBN to_TO be_VB responsive_JJ to_TO oxidative_JJ conditions_NNS ,_, under_IN which_WDT cysteine_NN
        residues_NNS are_VBP oxidized_JJ to_TO form_VB cysteine-sulfinic_JJ acids_NNS ._. There_EX is_VBZ some_DT discussion_NN about_IN which_WDT
        cysteine_NN residue_NN is_VBZ oxidized_JJ ;_: the_DT most_RBS likely_JJ is_VBZ cysteine_NN 106_CD ,_, which_WDT is_VBZ present_JJ in_IN a_DT
        nucleophile_NN elbow_NN in_IN the_DT protein_NN ._. We_PRP have_VBP suggested_VBN that_IN modifying_VBG this_DT residue_NN precludes_VBZ
        DJ-_NNP 1_CD oxidation_NN under_IN mild_JJ conditions_NNS and_CC also_RB blocks_VBZ the_DT neuroprotective_JJ activity_NN of_IN DJ-_NNP 1_CD
        against_IN mitochondrial_NN toxicity_NN (_( Canet-_NNP Aviles_NNP et_CC al_NN ._. 2004_CD )_) ._. Therefore_RB ,_, whatever_WDT the_DT function_NN
        of_IN DJ-_NNP 1_CD ,_, it_PRP seems_VBZ to_TO be_VB related_VBN to_TO oxidation_NN ._. In_IN support_NN of_IN this_DT idea_NN ,_, cells_NNS with_IN 
        DJ-_NNP 1_CD knocked_VBD out_IN show_NN increased_VBD sensitivity_NN to_TO oxidative_JJ stress_NN (_( Yokota_NNP
        et_CC al_NN ._. 2003_CD )_) ._. Another_DT study_NN published_VBN in_IN this_DT issue_NN of_IN 
        PLoS_NNP Biology_NNP shows_VBZ that_IN dopamine_NN neurons_NNS differentiated_JJ from_IN embryonic_JJ
        stem_NN cells_NNS lacking_VBG functional_JJ DJ-_NNP 1_CD are_VBP especially_RB sensitive_JJ to_TO oxidative_JJ stress_NN (_( Martinat_NNP
        et_CC al_NN ._. 2004_CD )_) ._.
        This_DT discussion_NN indicates_VBZ that_IN the_DT genes_NNS responsible_JJ for_IN recessive_JJ parkinsonism_NN all_DT have_VBP
        different_JJ functions_NNS but_CC are_VBP all_DT ,_, in_IN a_DT broad_JJ sense_NN ,_, neuroprotective_JJ ._. A_DT very_RB difficult_JJ
        question_NN to_TO answer_VB is_VBZ whether_IN this_DT has_VBZ anything_NN to_TO do_VB with_IN α-synuclein_JJ ._. We_PRP have_VBP shown_VBN that_DT
        parkin_NN can_MD mitigate_VB the_DT toxicity_NN of_IN mutant_JJ α-synuclein_JJ (_( Petrucelli_NNP et_CC al_NN ._. 2002_CD )_) ._. Although_IN
        there_EX are_VBP reports_NNS that_IN a_DT proportion_NN of_IN α-synuclein_JJ is_VBZ a_DT parkin_NN substrate_NN (_( Shimura_NNP et_CC al_NN ._.
        2001_CD )_) ,_, most_JJS of_IN the_DT protein_NN is_VBZ not_RB degraded_JJ by_IN the_DT ubiquitin-proteasome_JJ system_NN ._. Recent_JJ
        evidence_NN points_NNS ,_, instead_RB ,_, to_TO an_DT important_JJ role_NN of_IN the_DT lysosome_NN ,_, the_DT other_JJ major_JJ pathway_NN
        within_IN cells_NNS for_IN degrading_JJ unwanted_JJ proteins_NNS ,_, in_IN clearing_NN α-synuclein_JJ (_( Cuervo_NNP et_CC al_NN ._. 2004_CD )_) ._.
        On_IN balance_NN ,_, therefore_RB ,_, there_EX is_VBZ no_DT direct_JJ evidence_NN that_IN parkin_NN controls_NNS α-synuclein_JJ
        toxicity_NN by_IN an_DT effect_NN on_IN protein_NN levels_NNS within_IN the_DT cell_NN ._. Furthermore_RB ,_, parkin_NN does_VBZ not_RB just_RB
        prevent_VB α-synuclein_JJ toxicity_NN :_: it_PRP is_VBZ beneficial_JJ against_IN several_JJ other_JJ stresses_VBZ (_( discussed_VBN in_IN
        Shen_NNP and_CC Cookson_NNP 2004_CD )_) ,_, leading_VBG to_TO the_DT possibility_NN that_IN this_DT protein_NN protects_VBZ neurons_NNS
        against_IN more_RBR than_IN just_RB the_DT processes_NNS implicated_VBN in_IN PD_NNP ._.
        It_PRP has_VBZ also_RB been_VBN suggested_VBN that_IN DJ-_NNP 1_CD can_MD prevent_VB the_DT accumulation_NN of_IN aggregated_JJ
        α-synuclein_JJ and_CC that_DT cysteine_NN 53_CD is_VBZ critical_JJ for_IN this_DT activity_NN (_( Shendelman_NNP et_CC al_NN ._. 2004_CD )_) ._.
        However_RB ,_, DJ-_NNP 1_CD is_VBZ not_RB just_RB a_DT chaperone_NN for_IN α-synuclein_JJ ;_: it_PRP can_MD also_RB promote_VB refolding_VBG of_IN
        citrate_NN synthase_NN ,_, glutathione_NN transferase_NN ,_, and_CC neurofilament_NN light_JJ ._. Other_JJ research_NN groups_NNS
        have_VBP reported_VBN similar_JJ findings_NNS (_( Olzmann_NNP et_CC al_NN ._. 2004_CD )_) ,_, although_IN there_EX are_VBP differences_NNS
        between_IN these_DT studies_NNS in_IN which_WDT cysteine_NN residues_NNS are_VBP thought_VBN to_TO be_VB required_VBN for_IN DJ-_NNP 1_CD
        function_NN ._. Given_VBN that_IN there_EX are_VBP some_DT differences_NNS in_IN these_DT results_NNS ,_, further_JJ clarification_NN of_IN
        the_DT role_NN for_IN DJ-_NNP 1_CD in_IN α-synuclein-mediated_JJ toxicity_NN is_VBZ needed_VBN ._. More_RBR generally_RB ,_, we_PRP have_VBP to_TO
        bear_VB in_IN mind_NN that_IN whether_IN recessive_JJ parkinsonism_NN has_VBZ anything_NN to_TO do_VB with_IN α-synuclein_JJ is_VBZ
        still_RB an_DT open_JJ question_NN ._. What_WP is_VBZ clear_JJ is_VBZ that_IN some_DT neurons_NNS rely_VBP on_IN 
        parkin_NN ,_, DJ-_NNP 1_CD ,_, or_CC 
        PINK_NNP 1_CD to_TO protect_VB themselves_PRP against_IN the_DT many_JJ stresses_NNS that_IN they_PRP face_VBP ._.
        However_RB ,_, mutations_NNS in_IN these_DT genes_NNS do_VBP not_RB cause_VB generalized_JJ neurodegeneration_NN ;_: in_IN fact_NN ,_, they_PRP
        tend_VBP to_TO be_VB more_RBR restricted_JJ and_CC less_RBR progressive_JJ than_IN ,_, for_IN example_NN ,_, α-synuclein_JJ mutations_NNS ._.
        This_DT suggests_VBZ ,_, at_IN least_JJS to_TO my_PRP$ mind_NN ,_, that_IN recessive_JJ mutations_NNS indicate_VBP something_NN about_IN the_DT
        neurons_NNS that_WDT are_VBP damaged_VBN in_IN these_DT disorders_NNS ._. Why_WRB is_VBZ this_DT of_IN more_JJR than_IN academic_JJ importance_NN ?_.
        Perhaps_RB by_IN identifying_VBG the_DT proximal_NN events_NNS that_WDT are_VBP sufficient_JJ to_TO cause_VB a_DT specific_JJ set_NN of_IN
        neurons_NNS to_TO degenerate_VB ,_, we_PRP might_MD begin_VB to_TO design_VB therapies_NNS that_WDT address_VBP the_DT underlying_VBG
        degeneration_NN in_IN PD_NNP and_CC not_RB just_RB the_DT consequences_NNS ._.
      
    
  
